beta
/PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)
Abstract

Abstract N/A

RelatedView All
Authors 16View All
CitationsView All
Citing-
Cited By-